Showing 1-10 of 114 results for "".

• Cosmetic Controversies: A CSF Update from the 2019 Meeting

  https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-controversies-a-csf-update/20121/
  Some of the leading minds in cosmetic surgery weigh in on the ongoing controversies in aesthetic patient care. David Goldberg, MD, JD, Zakia Rhaman, MD, Hema Sundaram, MD, and Julie Woodward, MD talk lasers, injectables, and influencers.
  • Video

• Tips for Filling the Jaw, Chin, and Mid-face

  https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-for-filling-the-jaw-chin-and-mid-face/23598/
  CSF faculty members share pearls for injecting new fillers.
  • Text

• Read My Lips: Contemporary Approaches to Perioral Rejuvenation

  https://practicaldermatology.com/topics/practice-management/readmylips-contemporary-approaches-to-perioral-rejuvenation/21042/
  • Text

• A First Look at Rotational Fractional Resection

  https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-first-look-at-rotational-fractional-resection/20383/
  A new technology offers a fresh approach to treatment of submental contouring.
  • Text

• Getting to Know Juvéderm Volbella XC

  https://practicaldermatology.com/topics/practice-management/getting-to-know-juvderm-volbella-xc/20864/
  CSF faculty members share Volbella pearls.
  • Text

• Cosmetics Challenge

  https://practicaldermatology.com/topics/general-topics/cosmetics-challenge/21793/
  • Text

• Recent Developments

  https://practicaldermatology.com/columns/recent-developments/the-game-of-drones/23021/
  • Text
• FDA Clears Candela's Vbeam 595 nm Pulsed Dye Laser for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Population
  https://practicaldermatology.com/news/fda-clears-vbeam-595-nm-pulsed-dye-laser-for-the-treatment-of-port-wine-stains-and-hemangiomas-in-the-pediatric-population/2461824/
  The U.S Food and Drug Administration has cleared candela’s Vbeam family of 595 nm wavelength pulsed dye lasers (PDL) to treat cutaneous capillary malformations, and infantile hemangiomas (IH)/congenital hemangiomas in the pediatric population (from birth – 21 years of age).
• Pierre Fabre Dermatologie Receives the Prix Galien Award for Pharmaceutical Research for Hemangiol
  https://practicaldermatology.com/news/pierre-fabre-dermatologie-receives-the-prix-galien-award-for-pharmaceutical-research-for-hemangiol/2459047/
  Pierre Fabre Dermatologie, a subsidiary of Pierre Fabre Dermo-Cosmetics, was distinguished  by the Prix Galien award (France) for Hemangiol, an oral pediatric propranolol solution specifically developed for some severe infantile hemangiomas. Hemangiol® was successively approved by Americ
• Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangioma
  https://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/
  Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring s

• Prev
• 1
• 2
• 3
• …
• 11
• 12
• Next